Cost-effectiveness of pharmacotherapy for smoking cessation

This briefing addresses the cost-effectiveness of smoking cessation interventions.

Analysis shows that when smoking cessation interventions are effective they are invariably also cost-effective. This is also the case for pharmacotherapy for smoking cessation, including nicotine replacement therapy (NRT), bupropion (Zyban) and varenicline (Champix).

Indeed, findings from economic analyses from the UK and elsewhere confirm that smoking cessation interventions, including pharmacotherapy, are among the most cost-effective health care interventions available.

Whilst smoking cessation interventions remain highly cost-effective, this briefing does not include cytisinicline and the data is not current. We have no reason to doubt that the conclusions still stand and it remains accessible in our archive.